pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib
Sun Yat-sen University
Sun Yat-sen University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Safety of Almonertinib, Subjects With Hyperuricemia, Renal Function Disorder, Acute-O
广州市新港西路135号, CN HQ
3,680 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 广州市新港西路135号, CN
- Employees
- 3,680
- Programs
- 19
- Drugs
- 25
- Patents
- 0
gemcitabine and cisplatin (Induction chemotherapy)
Phase 3 · small molecule · Nasopharyngeal Carcinoma
gemcitabine and cisplatin (Induction chemotherapy) for Nasopharyngeal Carcinoma is a Phase 3 program (small_molecule) at Sun Yat-sen University with 1 ClinicalTrials.gov record(s).
Internal code 2022-FXY-298
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Nasopharyngeal Carcinoma
- Status
- active
- Trials
- 1